ABSTRACT
Coronary intervention may be one effective strategy to optimize the cardiac risk patient scheduled for noncardiac surgery ( fig. 1 ). Available studies confirm a benefit of such an intervention if the indications for preoperative testing and intervention are independent from the surgical procedure (1, 2, 3) . A net benefit of a preoperative intervention only exists if morbidity/mortality of noncardiac surgery without any pre-operative intervention (= immediate clearance for surgery) is ≥ morbidity/mortality of noncardiac surgery after extensive testing and intervention ( fig. 2 ). Patients with low and intermediate risk procedures will not benefit. Outcome of patients after prophylactic revascularization before noncardiac surgery seems not be different from patients with conservative management (4, 5) .
There has been a dramatic change in the landscape of coronary intervention in the last decade. Percutaneous coronary intervention dominates over coronary artery bypass graft surgery, and PTCA with coronary artery stenting is the preferred interventional strategy. Therefore, anesthesiologists are more Figure 1 Preoperative optimization of the coronary risk patient scheduled for noncardiac surgery and more confronted with patients after recent coronary artery stenting scheduled for noncardiac surgery. Coronary artery stenting implicates the need for dual antiplatelet drug therapy, usually with clopidogrel and aspirin. Discontinuation of dual antiplatelet drug therapy increases the risk of perioperative stent thrombosis and continuation of the risk of surgical bleeding. Kaluza et al reported an alarming 20% perioperative mortality rate (6). In 2003 Wilson et al published a retrospective study of 207 patients. 4% of them suffered from cardiac events inclusive of 6 patients, who died (7). Recently, Vicenzi et al published a prospective outcome study enrolling all patients with a coronary artery stent within one year before NCS. 44% suffered from complications after surgery, 4.9% died (8, fig. 3 ). All, but two (bleeding only) adverse events were of cardiac nature. The risk of suffering an event was 2.11 fold greater in patients with recent stents (< 35 days before surgery) as compared with PCI more than 90 days before surgery. In the nonsurgical setting cardiologic trials documented greater bleeding risk when clopidogrel and aspirin were combined, compared to aspirin alone (9) . Most of the surgical data comes from clinical studies in patients undergoing CABG-surgery (10, 11) . Clopidogrel, a thienopyridin, inhibits platelet aggregation by irreversible blockade of adenosin diphosphat mediated platelet function. Normalization depends on the new platelet population. Most CABG-studies demonstrated that clopidogrel given within 4 to 5 days before CABG-surgery increased transfusion requirements and prolonged ICU-stay (10, 11) .
Recommended dual antiplatelet drug regime after stent implantation
The ACC/AHA Guidelines from 2002 concluded that there is uncertainty regarding how much time should pass between PCI and NCS procedures. If a coronary stent is used, a delay of at least two weeks and ideally 4 to 6 weeks should occur before NCS to allow 4 full weeks of dual antiplatelet therapy and reendothelialization of the stent to be completed or nearly so (12) . The new Guidelines of the European Society of Cardiology for percutaneous coronary artery intervention recommend that after implantation of a bare metal stent clopidogrel must be continued for 3 to 4 weeks and ASA lifelong, after drugeluting stents clopidogrel and ASA should be administered for 6 to 12 months to avoid late vessel thrombosis (13) . The new ACC/AHA 2005 Guideline update for percutaneous coronary intervention recommends that in patients who have undergone PCI, clopidogrel 75 mg daily should be given for at least 1 month after bare-metal stent implantation (unless the patient is at an increased risk for bleeding; then it should be given for a minimum of 2 weeks), 3 months after sirolimus stent implantation, and 6 months after paclitaxel stent implantation, and ideally up to 12 months in patients who are not at high risk of bleeding (level of evidence B) (14) .
Perioperative management
Currently, many case reports and retrospective studies are available but no large prospective randomized trials. Therefore, we have to rely on recommendations of task forces and expert opinions (12) (13) (14) . Basically, when assessing the perioperative risk of patients with recent coronary artery stenting before noncardiac surgery we have to plot the risk of thrombosis vs. the risk of bleeding (fig. 4) . Dual antiplatelet regime can be stopped, changed or continued according to this assessment. Figure 4 Algorithm for preoperative management of patients after PCI with dual antiplatelet drug therapy.
